Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 25.25
Bid: 25.00
Ask: 25.50
Change: -2.00 (-7.34%)
Spread: 0.50 (2.00%)
Open: 26.75
High: 26.75
Low: 25.25
Prev. Close: 27.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

Tue, 23rd Nov 2021 16:21

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and not separately reported by Alliance News:

----------

MaxCyte Inc - Maryland-based platform for cell-based research - Richard Douglas, who was promoted to chair earlier this month, buys 20,000 shares at average USD11.12, worth USD222,480, on Monday. The purchase on Nasdaq in New York is his only share holding, though he also has 131,600 stock options.

----------

Harbour Energy PLC - North Sea-focused oil and gas - Non-Executive Director Anne Stevens buys 30,000 shares at average 400.05p, worth GBP120,016, on Monday. The purchase is her only holding.

----------

James Cropper PLC - paper products manufacturer based in Cumbria - Chair Mark Cropper buys 3,700 shares at GBP15.00, worth GBP55,500, on Friday last week. The shares were bought from two members of the Cropper family, which are part of the concert party, so his beneficial shareholding remains unchanged at 1.9 million shares, a 19% stake. The total interest of the concert party is 3.6 million shares, a 38% stake.

----------

Ryanair Holdings PLC - Dublin-based airline - Non-Executive Director Geoff Doherty buys 3,000 shares at EUR15.84, worth EUR47,505, on Friday last week in Dublin.

----------

Anglo Asian Mining PLC - gold, copper and silver producer in Azerbaijan - Non-Executive Director John Monhemius buys 25,000 shares at 112.90p, worth GBP28,225, on Tuesday. Monhemius now has 366,890 shares, a 0.3% stake.

----------

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Non-Executive Chair Stephen Parker buys 277,777 shares at 3.6p, worth GBP10,000, on Tuesday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.